Astellas, Seattle Genetics ADC could provide new option for checkpoint non-responders in bladder cancer

Data presented at ASCO on Monday for Astellas and Seattle Genetics' enfortumab vedotin showed that metastatic bladder cancer patients who don't respond or relapse after PD-1/PD-L1 therapy could soon have a new treatment option.

In the first cohort of 125 patients in the pivotal Phase II EV-201 trial of the antibody-drug conjugate, the objective response rate (ORR) was 44%, in line with previously disclosed data; 12% of patients had a complete response (CR). The median duration of response was 7.6 months and median overall survival (OS) was 11.7 months (see "Seattle Genetics, Astellas ADC Heading for Bladder Cancer Submission")...